Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENERGI-F703EB Cream is an investigational topical cream formulation of adenine developed by Energenesis Biomedical for the treatment of epidermolysis bullosa (EB), including epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), and dystrophic epidermolysis bullosa (DEB). The drug acts as an adenosine 5'-monophosphate-activated protein kinase (AMPK) activator. By delivering adenine topically, it serves as a substrate to replenish intracellular adenosine triphosphate (ATP) levels in epithelial cells, thereby promoting cell migration, collagen deposition, and accelerating wound healing and tissue repair. ENERGI-F703EB has received Orphan Drug and Rare Pediatric Disease designations from the US FDA, as well as orphan designation from the EMA, and is currently in Phase II clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ENERGI-F703EB Cream.